Ozempic Twist: Cancer Risk Plunges?

Doctor filling syringe with vaccine from vial.

A major new study suggests that Ozempic and similar weight-loss drugs may cut breast cancer risk by roughly 30% — but scientists are urging caution before the headlines outrun the evidence.

At a Glance

A Penn Medicine analysis of more than 110,000 women found GLP-1 drug users were about 30% less likely to develop breast cancer than nonusers.
The study was observational and retrospective, meaning it identifies an association — not a proven cause-and-effect relationship.
Researchers did not account for GLP-1 drug type, duration of use, genetic risk factors, or cancer stage, leaving key questions unanswered.
Separate research suggests GLP-1 drugs may also improve survival and reduce recurrence in existing breast cancer patients, though evidence remains early-stage.

What the Penn Medicine Study Found

Researchers at Penn Medicine presented findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting showing that women taking glucagon-like peptide-1 (GLP-1) receptor agonist medications — drugs like Ozempic and Wegovy — were significantly less likely to develop breast cancer. The analysis examined records from more than 110,000 women between the ages of 45 and 80, finding 35.1% lower odds of breast cancer in the full group and 30.5% lower odds in a matched comparison cohort. ^[2]

The study adjusted for major variables including age, body mass index, diabetes status, and breast density — factors that could otherwise skew results. Lead researcher Elizabeth McDonald, MD, PhD, described the findings as a meaningful signal, but was careful to note that the analysis is observational in nature and does not definitively confirm that GLP-1 drugs cause the reduction in cancer risk. Penn Medicine stated the study “sets the stage for a multi-site clinical trial” to explore the question further. ^[2]

Why Scientists Are Pumping the Brakes

The core limitation here is one that applies across medical research: association is not causation. The Penn study relied on electronic health record data — a retrospective design that cannot rule out confounding factors the researchers didn’t measure. The analysis did not account for which specific GLP-1 drug women were taking, how long they used it, their genetic cancer risk, or the type and stage of any cancer that developed. These are not minor gaps — they are the difference between a promising hypothesis and a proven medical intervention. ^[2] ^[4]

A separate review published in a National Institutes of Health database examined GLP-1 use across roughly 46,000 treated patients and 41,000 controls and found no increased breast cancer risk — but also stopped short of claiming a protective benefit. ^[3] The broader scientific literature on GLP-1s and cancer remains a mixed picture, with signals appearing across multiple cancer types but prospective clinical trials — the gold standard for establishing causation — still largely absent. ^[6] ^[7]

Beyond Prevention: Survival and Recurrence Data

The breast cancer conversation around GLP-1 drugs extends beyond prevention. A study published in JAMA Network Open found that GLP-1 receptor agonist use was associated with a lower overall risk of death over a 10-year follow-up period among breast cancer patients — suggesting potential benefits that go beyond blood sugar control and weight loss. ^[9] Researchers described the drugs as possibly offering “protective benefits beyond glycemic and weight control,” though they too stopped short of declaring causation. ^[9]

#Weightloss drugs can cut #breastcancer risk by up to 30%, studies suggest https://t.co/MgPFrUiDMH One analysis found those who took #GLP1 medications were 30% less likely to develop breast #cancer, the world’s most common form of the disease, compared with those not taking…

— Health Point (@aliya_Hshah) June 6, 2026

There is also a complication worth noting. Separate research presented at a breast cancer symposium found that GLP-1 use among patients already on hormonal therapy was linked to a higher rate of side effects, including hot flashes. ^[5] That finding underscores a recurring theme in this research landscape: GLP-1 drugs may offer meaningful benefits in some contexts while introducing trade-offs in others, and patients currently in treatment should consult their physicians rather than draw conclusions from population-level studies. The science is moving fast, but it has not yet caught up to the headlines. ^[6]